SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing agreement with Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a fellow Chinese pharmaceutical company. The deal concerns TargetRx’s TGRX-326, an ALK/ROS1 dual receptor tyrosine kinase inhibitor currently at the clinical stage.
According to the agreement, Simcere will secure exclusive commercialization rights for the drug in mainland China. The transaction includes an upfront payment of USD 20 million to TargetRx, with the potential for additional promotion service fees.
TGRX-326 is a third-generation anaplastic lymphoma kinase (ALK) inhibitor developed in-house by TargetRx. The drug has demonstrated promising anti-tumor activity and safety in both pre-clinical and Phase I clinical studies. Notably, TGRX-326’s ability to efficiently penetrate the blood-brain barrier positions it as a candidate with significant therapeutic potential for patients with non-small cell lung cancer brain metastases.
This licensing deal underscores the growing interest in targeted therapies for oncology and highlights the strategic partnerships that are increasingly common in China’s pharmaceutical industry. It also reflects the commitment of both companies to advancing innovative treatments and improving patient outcomes. – Flcube.com
